An expanded study of blood and prostate cancer tissue samples from the same patients will be needed to distinguish between true- and false-negative results of our combined VTX-1-AdnaDetect assay and will need to include patients with lower tumor burden than in this study cohort, which was enriched for patients with high PSA. Here, KLK3 is linked to neoplasm.